Do the 2013 United States Preventive Services Task Force guidelines for lung cancer screening fail high-risk African American smokers? An institutional retrospective observational cohort study

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Aswani Thurlapati ◽  
Carol S. Velez-Martinez ◽  
Samina Hirani ◽  
Jade Abad ◽  
Runhua Shi ◽  
...  
Keyword(s):  
United States ◽  
Lung Cancer ◽  
African American ◽  
Cohort Study ◽  
High Risk ◽  
Task Force ◽  
Lung Cancer Screening ◽  
Observational Cohort Study ◽  
Observational Cohort ◽  
Retrospective Observational Cohort Study

Potential Role for Valproate in the Treatment of High-Risk Brain Tumors of Childhood—Results from a Retrospective Observational Cohort Study

2011 ◽  
Vol 28 (7) ◽  
pp. 556-570 ◽  
Author(s):  
Francisco Helder Cavalcante Felix ◽  
Nadia Mendonça Trompieri ◽  
Orlandira Leite de Araujo ◽  
Karine Martins da Trindade ◽  
Juvenia Bezerra Fontenele
Keyword(s):  
Cohort Study ◽  
High Risk ◽  
Brain Tumors ◽  
Potential Role ◽  
Observational Cohort Study ◽  
Observational Cohort ◽  
Retrospective Observational Cohort Study

scholarly journals Trends in the prescription of systemic anticancer therapy and mortality among patients with advanced non-small cell lung cancer: a real-world retrospective observational cohort study from the I-O optimise initiative

BMJ Open ◽  
2021 ◽  
Vol 11 (5) ◽  
pp. e043442
Author(s):  
Michael Snee ◽  
Sue Cheeseman ◽  
Matthew Thompson ◽  
Majid Riaz ◽  
Will Sopwith ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cohort Study ◽  
Advanced Nsclc ◽  
Performance Status ◽  
Anticancer Therapy ◽  
Small Cell ◽  
Observational Cohort Study ◽  
Small Cell Lung ◽  
Observational Cohort ◽  
Retrospective Observational Cohort Study

ObjectivesTo assess how a decade of developments in systematic anticancer therapy (SACT) for advanced non-small cell lung cancer (NSCLC) affected overall survival (OS) in a large UK University Hospital.DesignReal-world retrospective observational cohort study using existing data recorded in electronic medical records.SettingA large National Health Service (NHS) university teaching hospital serving 800 000 people living in a diverse metropolitan area of the UK.Participants2119 adults diagnosed with advanced NSCLC (tumour, node, metastasis stage IIIB or IV) between 2007 and 2017 at Leeds Teaching Hospitals NHS Trust.Main outcomes and measuresOS following diagnosis and the analysis of factors associated with receiving SACT.ResultsMedian OS for all participants was 2.9 months, increasing for the SACT-treated subcohort from 8.4 months (2007–2012) to 9.1 months (2013–2017) (p=0.02); 1-year OS increased from 33% to 39% over the same period for the SACT-treated group. Median OS for the untreated subcohort was 1.6 months in both time periods. Overall, 30.6% (648/2119) patients received SACT; treatment rates increased from 28.6% (338/1181) in 2007–2012 to 33.0% (310/938) in 2013–2017 (p=0.03). Age and performance status were independent predictors for SACT treatment; advanced age and higher performance status were associated with lower SACT treatment rates.ConclusionAlthough developments in SACT during 2007–2017 correspond to some changes in survival for treated patients with advanced NSCLC, treatment rates remain low and the prognosis for all patients remains poor.

Sign in / Sign up

Export Citation Format

Share Document